![[up]](/style/images/multi_up.png)
Up a levelGroup by: Item Type | Date
Jump to: Journal article
Number of items: 4.
Journal article
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Vol. 146: pp. 95-106
Kasenda, B.; Ihorst, G.; Schrörs, R.; Korfel, A.; Schmidt-Wolf, I.; Egerer, G.; Baumgarten, L. von; Röth, A.; Blöhdorn, J.; Möhle, R.; Binder, M.; Keller, U.; Lamprecht, M.; Pfreundschuh, M.; Valk, E.; Fricker, H.; Schorb, E.; Fritsch, K.; Finke, J. und Illerhaus, G.
(2017):
High-dose chemotherapy with autologous hämatopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
In: Leukemia, Vol. 31, No. 12: pp. 2623-2629
Hecht, M.; Hahn, D.; Beutner, D.; Reichert, D.; Göhler, T.; Wurm, R.; Welslau, M.; Renziehausen, L.; Balermpas, P.; Bergmann, T.; Assmann, M.; Belka, C.; Orlowski, K.; Finzsch, M.; Illerhaus, G. und Fietkau, R.
(2016):
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial).
In: Annals of Oncology, Vol. 27
Hecht, M.; Hahn, D.; Beutner, D.; Reichert, D.; Göhler, T.; Wurm, R.; Welslau, M.; Renziehausen, L.; Balermpas, P.; Bergmann, T.; Aßmann, M.; Belka, C.; Orlowski, K.; Finzsch, M.; Illerhaus, G. und Fietkau, R.
(2016):
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial).
In: Oncology Research and Treatment, Vol. 39: p. 171